Xeris Biopharma Holdings, Inc. 4

Kevin McCulloch, President and COO of Xeris Biopharma (XERS), sold 15,000 shares of common stock at about $8.016 per share under a Rule 10b5-1 plan.

On August 3, 2026, Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, Inc., sold 15,000 shares of the company’s common stock at a weighted average price of approximately $8.016 per share under a pre-established Rule 10b5-1 trading plan, for gross proceeds of about $120,240. Following this sale, he reported direct beneficial ownership of 1,676,126 shares of common stock, and there remains an additional 25,000 shares reported as indirectly owned through his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest. The sale was executed in multiple trades within a price range of $8.00 to $8.15 per share, and the Form 4 notes that detailed price breakdowns are available upon request, indicating a routine, plan-based disposition rather than an opportunistic trade.

Filing Facts

CIK

1867096

Ticker

XERS

Form

4

Source Type

fda

Accession

0001867096-26-000059

Alert Tier

6